NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - CONSIDERATIONS FOR CLINICAL-TRIALS

被引：71
|
作者：
MOLLER, HJ
VANPRAAG, HM
AUFDEMBRINKE, B
BAILEY, P
BARNES, TRE
BECK, J
BENTSEN, H
EICH, FX
FARROW, L
FLEISCHHACKER, WW
GERLACH, J
GRAFFORD, K
HENTSCHEL, B
HERTKORN, A
HEYLEN, S
LECRUBIER, Y
LEONARD, JP
MCKENNA, P
MAIER, W
PEDERSEN, V
RAPPARD, A
REIN, W
RYAN, J
NIELSEN, MS
STIEGLITZ, RD
WEGENER, G
WILSON, J
机构：
[1] BOEHRINGER INGELHEIM DEUTSCHLAND GMBH, KLIN FORSCH INGELHEIM, D-55216 INGELHEIM, GERMANY
[2] UNIV BONN, NERVENKLIN, D-53127 BONN, GERMANY
[3] ACAD PSYCHIAT CTR, 6202 AZ MAASTRICHT, NETHERLANDS
[4] SCHERING AG, D-13353 BERLIN, GERMANY
[5] CHARING CROSS & WESTMINSTER MED SCH, LONDON, ENGLAND
[6] SYNTHELABO RECH, D-81925 MUNICH, GERMANY
[7] GAUSTAD HOSP, N-0320 OSLO, NORWAY
[8] ZENECA PHARMACEUT, MACCLESFIELD, CHESHIRE, ENGLAND
[9] UNIV INNSBRUCK, KLIN, A-6020 INNSBRUCK, AUSTRIA
[10] ST HANS HOSP, DK-4000 ROSKILDE, DENMARK
[11] ASTRA ARCUS AB, S-15185 SODERTALJE, SWEDEN
[12] HOECHST AG, D-65929 FRANKFURT, GERMANY
[13] JANSSEN RES FDN, B-2340 BEERSE, BELGIUM
[14] HOP LA PITIE SALPETRIERE, U302, F-75651 PARIS 13, FRANCE
[15] FULBOURNE HOSP, CAMBRIDGE CB1 5EF, ENGLAND
[16] UNIV MAINZ, PSYCHIAT KLIN, D-55131 MAINZ, GERMANY
[17] H LUNDBECK & CO AS, DK-2500 COPENHAGEN, DENMARK
[18] JANSSEN GMBH, D-41470 NEUSS, GERMANY
[19] SYNTHELABO PARIS, F-92225 BAGNEUX, FRANCE
[20] NOVO NORDISK AS, DK-2760 MALOV, DENMARK
[21] UNIV FREIBURG, PSYCHIAT KLIN, D-79104 FREIBURG, GERMANY
[22] E MERCK AG, D-64293 DARMSTADT, GERMANY
[23] GLAXO GRP RES LTD, GREENFORD UB6 0HE, MIDDX, ENGLAND
来源：
PSYCHOPHARMACOLOGY | 1994年 / 115卷 / 1-2期
关键词：
SCHIZOPHRENIA; NEGATIVE SYMPTOMS; CLINICAL TRIALS; PSYCHIATRIC STATUS RATING SCALES; NEUROLEPTICS;
D O I：
10.1007/BF02244775
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treatment of negative symptoms. Some degree of standardization would improve comparability of studies and aid the development of new compounds. Patients included in such studies should have displayed negative symptoms for at least 6 months. Depressive symptoms, positive schizophrenic symptoms and extrapyramidal signs may all in fluence or be confused with negative symptoms and may respond to treatment; they should be at a low level at baseline and should be measured during the study period. Studies should last at least 8 weeks. Several scales are available for measuring negative symptoms and are reviewed; a global impression score should be used additionally.
引用
收藏
页码：221 / 228
页数：8
相关论文
共 50 条
12345